Description
INTRODUCTION
Empagliflozin, sold under the trade name Jardiance among others, is a medication used together with diet and exercise to treat type 2 diabetes. It is less preferred than metformin and sulfonylureas. It may be used together with other medications such as metformin or insulin. It is not recommended for type 1 diabetes. It is taken by mouth.Common side effects include urinary tract infections, fungal infections of the groin, and joint pains. Rarer but more serious side effects include a skin infection of the groin called Fournier's gangrene and a form of diabetic ketoacidosis with normal blood sugar levels. Use in pregnancy and breastfeeding is not recommended. Use is not recommended in those with significant kidney disease, though it may help slow the progression of mild kidney problems. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar lost in the urine.
Empagliflozin is a medication used together with diet and exercise to treat type 2 diabetes. It is less preferred than metformin and sulfonylureas. It may be used together with other medications such as metformin or insulin.
Empagliflozin, sold under the trade name Jardiance among others, is a medication used together with diet and exercise to treat type 2 diabetes. It is less preferred than metformin and sulfonylureas. It may be used together with other medications such as metformin or insulin. It is not recommended for type 1 diabetes. It is taken by mouth.Common side effects include urinary tract infections, fungal infections of the groin, and joint pains. Rarer but more serious side effects include a skin infection of the groin called Fournier's gangrene and a form of diabetic ketoacidosis with normal blood sugar levels. Use in pregnancy and breastfeeding is not recommended. Use is not recommended in those with significant kidney disease, though it may help slow the progression of mild kidney problems. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar lost in the urine.
| Product name | Empagliflozin | |
| Tests | Specification | Results |
| Identification | Musculine reaction | Conform |
| Description | White powder | Conform |
| Clarity and Color | Should conform | Conform |
| Specific rotation | -92°~-109° | -97.5° |
| Other Impurities | ≤0.5% | 0.16% |
| Loss on drying | ≤3.0% | 2.00% |
| Limit of(R)-olfx | ≤1.0% | 0.45% |
| Residue on ignition | ≤0.2% | 0.05% |
| Heavy metals | ≤0.002% | Conform |
| Assay | ≥98.5% | 99.00% |
